- Home
- FENC vs IGI Comparison
FENC vs IGI Comparison
Compare FENC & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- IGI
- Stock Information
- Founded
- FENC 1996
- IGI 2009
- Country
- FENC United States
- IGI United States
- Employees
- FENC N/A
- IGI N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- IGI Investment Managers
- Sector
- FENC Health Care
- IGI Finance
- Exchange
- FENC Nasdaq
- IGI Nasdaq
- Market Cap
- FENC 156.9M
- IGI 174.9M
- IPO Year
- FENC 2001
- IGI N/A
- Fundamental
- Price
- FENC $5.08
- IGI $16.12
- Analyst Decision
- FENC Strong Buy
- IGI
- Analyst Count
- FENC 2
- IGI 0
- Target Price
- FENC $14.00
- IGI N/A
- AVG Volume (30 Days)
- FENC 87.7K
- IGI 33.9K
- Earning Date
- FENC 05-13-2025
- IGI 01-01-0001
- Dividend Yield
- FENC N/A
- IGI 4.79%
- EPS Growth
- FENC N/A
- IGI N/A
- EPS
- FENC N/A
- IGI N/A
- Revenue
- FENC $47,538,000.00
- IGI N/A
- Revenue This Year
- FENC $2.68
- IGI N/A
- Revenue Next Year
- FENC $71.63
- IGI N/A
- P/E Ratio
- FENC N/A
- IGI N/A
- Revenue Growth
- FENC 123.69
- IGI N/A
- 52 Week Low
- FENC $3.96
- IGI $15.13
- 52 Week High
- FENC $10.07
- IGI $17.79
- Technical
- Relative Strength Index (RSI)
- FENC 34.36
- IGI 40.08
- Support Level
- FENC $5.02
- IGI $15.76
- Resistance Level
- FENC $5.50
- IGI $16.22
- Average True Range (ATR)
- FENC 0.41
- IGI 0.31
- MACD
- FENC -0.03
- IGI -0.02
- Stochastic Oscillator
- FENC 22.22
- IGI 40.00
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.